Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Waldenstrom Macroglobulinemia
|
15 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.100 | 1.000 | 53 | 2012 | 2019 | ||||
Diffuse Large B-Cell Lymphoma
|
127 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.100 | 0.895 | 19 | 2013 | 2019 | ||||
Malignant lymphoma - lymphoplasmacytic
|
10 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.100 | 0.944 | 18 | 2012 | 2019 | ||||
Lymphoma
|
91 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.100 | 0.917 | 12 | 2013 | 2019 | ||||
Chronic Lymphocytic Leukemia
|
291 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.080 | 1.000 | 8 | 2013 | 2019 | ||||
Neoplasms
|
1644 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.080 | 1.000 | 8 | 2012 | 2019 | ||||
Adult Diffuse Large B-Cell Lymphoma
|
46 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.070 | 1.000 | 7 | 2013 | 2019 | ||||
Adult Lymphoma
|
66 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.070 | 1.000 | 7 | 2014 | 2019 | ||||
B-Cell Lymphomas
|
42 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.070 | 1.000 | 7 | 2013 | 2018 | ||||
Childhood Lymphoma
|
66 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.070 | 1.000 | 7 | 2014 | 2019 | ||||
IgM monoclonal gammopathy of uncertain significance
|
3 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.060 | 1.000 | 6 | 2013 | 2019 | ||||
Lymphoproliferative Disorders
|
14 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.060 | 0.833 | 6 | 2013 | 2015 | ||||
Marginal Zone B-Cell Lymphoma
|
25 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.060 | 1.000 | 6 | 2013 | 2019 | ||||
Monoclonal Gammopathy of Undetermined Significance
|
20 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.050 | 0.800 | 5 | 2012 | 2019 | ||||
Multiple Myeloma
|
865 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.050 | 1.000 | 5 | 2012 | 2018 | ||||
Primary central nervous system lymphoma
|
4 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.050 | 1.000 | 5 | 2018 | 2019 | ||||
Monoclonal Gammapathies
|
2 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.040 | 1.000 | 4 | 2012 | 2017 | ||||
Splenic Marginal Zone B-Cell Lymphoma
|
4 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.040 | 0.750 | 4 | 2013 | 2017 | ||||
Bing-Neel syndrome
|
1 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.030 | 1.000 | 3 | 2014 | 2019 | ||||
Carcinogenesis
|
355 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.030 | 1.000 | 3 | 2016 | 2018 | ||||
Mucosa-Associated Lymphoid Tissue Lymphoma
|
13 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.030 | 0.667 | 3 | 2013 | 2017 | ||||
Paraproteinemias
|
9 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.030 | 1.000 | 3 | 2015 | 2019 | ||||
Activated B-cell type diffuse large B-cell lymphoma
|
2 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.020 | 1.000 | 2 | 2014 | 2014 | ||||
Hematologic Neoplasms
|
60 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.020 | 1.000 | 2 | 2014 | 2016 | ||||
Leukemogenesis
|
25 | 0.572 | 0.520 | 3 | 38141150 | stop lost | T/C | snv | 5.2E-05 | 7.0E-06 | 0.020 | 1.000 | 2 | 2014 | 2020 |